Jasper Therapeutics, Inc.
JSPRW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $187.1K in total; no superinvestor holds it.
Other share classesJSPR
Q3 2023 vs. Q2 2023
How the institutions holding Jasper Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 11 | 8 | −3 |
| Shares | 2.37M | 2.40M | +27.9K (+1.2%) |
| Value | $344.6K | $120.7K | −$223.9K (−65.0%) |
New holders (1)
Institutions that held Jasper Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 37 | $2 | 0.00% |
Sold out (4)
Institutions that held Jasper Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Highbridge Capital Management LLC | – | $12.8K |
| Equitec Proprietary Markets, LLC | 33,586 | $4.13K |
| Morgan Stanley | 100 | $12 |
| Advisor Group Holdings, Inc. | 50 | $5 |